Akums Subsidiary Leases Haridwar Site for Operations Boost

Lease Details

Akums Drugs and Pharmaceuticals Ltd. reported that its wholly-owned subsidiary, Pure and Cure Healthcare Private Limited, executed a lease deed for an industrial plot in Haridwar, Uttarakhand. The lease deed was executed on April 28, 2026. The property, located at Plot No. 36, Sector 8A, IIE SIDCUL, covers about 4050 square meters and includes both land and a building. This plot is strategically located next to the subsidiary's current manufacturing facility.

Strategic Importance

This lease agreement marks a step toward enhancing Pure and Cure Healthcare's operational capacity. Acquiring space next to its current plant could allow the subsidiary to streamline operations, increase production, or house new manufacturing processes. This move supports Akums' broader strategy for capacity expansion and strengthening its manufacturing footprint.

Company Background

Akums Drugs and Pharmaceuticals, India's largest Contract Development and Manufacturing Organization (CDMO), has been actively pursuing capacity expansion and global market penetration. In FY25, the company invested ₹272 crore in capital expenditure, boosting its annual production capacity to 49.6 billion units. Its subsidiary, Pure and Cure Healthcare, is an established pharmaceutical manufacturer operating its own facility in Haridwar, Uttarakhand.

Lease Impact

This lease provides Pure and Cure Healthcare Private Limited with enhanced operational space. The plot's adjacency to the existing facility offers potential for increased manufacturing output and efficiency, strengthening Akums' presence in the Haridwar industrial hub and supporting ongoing business operations and future growth initiatives.

Potential Risks

The lease deed was executed 'for purchasing an industrial plot,' wording that requires further clarification from the company. Akums Drugs and Pharmaceuticals is currently undergoing an Income Tax search and seizure operation, initiated in January 2025. The impact of this operation remains unascertainable. The company also paid a fine to the NSE in September 2025 for past non-compliance regarding board composition.

Competitive Landscape

Akums operates in a competitive landscape alongside major Indian pharmaceutical players including Sun Pharmaceutical Industries, Dr. Reddy's Laboratories, Cipla, Divi's Laboratories, and Aurobindo Pharma. These competitors also focus on manufacturing excellence and capacity expansion, with many maintaining significant domestic and international operations.

Looking Ahead

Key developments to track include clarification from Akums regarding the precise wording used in the lease deed, specifically 'for purchasing an industrial plot.' Investors will also want details on how Pure and Cure Healthcare will utilize this expanded space, updates on the ongoing Income Tax investigation and any potential financial impact, and further announcements regarding Akums' broader expansion strategies, both domestically and internationally.